PUBLIC COMPANY
save$TERNTerns Pharmaceuticals, Inc.
$TERN52.95-0.03%Foster City, CA, USupdated 2mo ago
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
14
approvals ytd
1
recalls ytd
12
Pipeline(3)
pipeline depth3 products
2Phase 21Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (2)
- Mar 16, 26option exerciseBurroughs Amy L. · Chief Executive Officer14,583 sh
- Mar 16, 26option exerciseBurroughs Amy L. · Chief Executive Officer14,583 sh
🐶 Hiring Signal
News
- BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearBMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.fiercebiotech · 21d ago
- Veradermics declares first efficacy win in women for hair loss drugVeradermics is for the first time reporting positive efficacy of its oral formulation of minoxidil in female pattern hair loss, which broadens the market potential of its flagship asset. In a mid-s…endpoints · 1mo ago
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.biopharma_dive · 2mo ago
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.biopharma_dive · 3mo ago
- Merck still sees ‘compelling’ outlook for Terns leukemia drugDespite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.biopharma_dive · 3mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that